心臓マーカー市場：製品、バイオマーカータイプ、エンドユーザー、適応症別-2024～2030年の世界予測

心臓マーカー市場規模は、2023年に38億1,000万米ドルと推定され、2024年には41億6,000万米ドルに達し、CAGR 9.71％で2030年には72億9,000万米ドルに達すると予測されています。

心臓マーカーは、さまざまな心臓の状態、特に心筋の損傷やストレスに関連する状態を診断・監視するために血液中で測定される物質または分子です。これらのマーカーは、病院や試験室などの臨床現場で、心血管系疾患の診断、予後予測、モニタリングの補助に用いられることが多いです。特に心筋梗塞やその他の急性冠症候群の診断に広く用いられています。心血管疾患（CVD）の正確かつ早期診断が重視されるようになり、心臓マーカー市場の評価も徐々に高まっています。心血管疾患の罹患率の上昇と世界の高齢者人口の増加が、心臓マーカーの市場需要に拍車をかけています。ポイントオブケア試験に対する需要の高まりと、設備の整ったラボや訓練を受けた人材を含む医療インフラの着実な発展が、世界的に業界の成長を後押ししています。しかし、心血管処置やソリューションに関連する高価格が市場導入に影響を与えています。バイオメディカル産業、特に診断技術の進化と、予防医療を促進することを目的とした政府の医療への取り組みやプログラムは、心臓マーカーの需要を拡大し、市場に大きな成長機会を生み出すのに役立っています。

製品：試薬とキットは心臓特異的タンパク質の定性的・定量的評価を提供する

ケミルミネッセンスイムノアッセイ（CLIA）システムは、トロポニン、CK-MB、ミオグロビンなどの高感度心臓マーカーを検出する高度な診断機器です。これらの装置は、標的抗原の存在下で特定の酵素と反応すると発光する発光基質を利用します。酵素結合免疫吸着測定法（ELISA）キットと装置は、心臓マーカーの検出と定量に不可欠です。これらのアッセイは、測定可能な比色変化を生じる酵素結合体反応に依存しています。ELISAシステムはスケーラビリティの面で柔軟性があり、その特異性と高感度で知られています。イムノクロマトグラフィーは、毛細管現象を介した膜に沿った粒子の移動を利用する、迅速で簡便な診断技術です。抗体や抗原を用いて、心臓マーカーのような特定のバイオマーカーを検出します。免疫蛍光法は、蛍光色素やマーカーを用いて特定の抗体や抗原の存在を検出する技術であり、心臓マーカーのより詳細で特異的な分析に用いられます。心臓マーカー検出のための試薬やキットは、様々な分析プラットフォームに最適化された幅広いイムノアッセイから構成されています。これらの消耗品には、心臓特異的タンパク質の定性・定量評価用に特別に設計された抗体、抗原、緩衝液、基質が含まれることが多いです。

バイオマーカータイプ：心不全の診断と管理のためのBNPとNT-proBNPバイオマーカーの高い採用率

BNPとNT-proBNPは心不全の診断と管理のためのバイオマーカーです。BNPは、心不全の典型的な体液過負荷による壁張力の上昇に反応して心室筋細胞から排出されます。これらのペプチドが低値で検出された場合、心臓のリスクと心不全の強い陰性予測値を示します。対照的に、高値は有害な心血管系イベントのリスク上昇を示します。クレアチンキナーゼ-MB（CK-MB）はクレアチンキナーゼ（CK）のアイソザイムで、心筋梗塞（MI）を診断するための伝統的なバイオマーカーの一つです。主に心筋細胞に存在し、心筋細胞が死滅すると血液中に増加します。高感度C反応性蛋白（Hs-CRP）は急性期蛋白であり、全身性の炎症を示す非特異的炎症性バイオマーカーです。心疾患のリスクやその他の心危険因子の評価によく用いられます。ミオグロビンは心筋傷害の早期マーカーであるが非特異的です。心筋梗塞の早期評価には、トロポニンなどのより特異的な心臓マーカーと併用するのが最も有用です。トロポニンIとTは、心筋収縮装置の一部である制御タンパク質であり、心筋傷害の特異性が高く感度の高いバイオマーカーです。

エンドユーザー：試験施設における心臓マーカーの大幅な利用

ラボラトリー試験施設は、一般的に高度な機器と包括的な試験を実施できる熟練したスタッフを備えています。病院と独立診断ラボがこのセグメントの主要コンポーネントです。これらは、心筋梗塞（心臓発作）や急性冠症候群を含む様々な心血管系疾患の診断に不可欠な、正確で大量の心臓マーカー試験サービスを提供しています。ポイント・オブ・ケア（POC）試験施設には、救急部、救急車、クリニック、医院などがあります。結果が即座に得られるため、迅速な臨床判断が可能となり、心臓救急の管理には不可欠です。トロポニン、BNP（B型ナトリウム利尿ペプチド）、Dダイマーなどの心臓マーカーのPOC試験は、心血管疾患の診断と管理に革命をもたらしました。心臓マーカー用POCTシステムはシンプルかつスピーディーに設計されており、急性期医療現場における意思決定のためのターンアラウンドタイムを短縮します。

適応症うっ血性心不全における心臓マーカー採用の可能性

うっ血性心不全（CHF）において、心臓マーカーは診断、予後、管理において非常に重要です。B型ナトリウム利尿ペプチド（BNP）とN末端-pro-BNP（NT-proBNP）は、CHFの疑いを確認し、呼吸困難の他の原因と鑑別し、重症度を評価するために使用される主要なバイオマーカーです。BNPまたはNT-proBNPの上昇は心不全と関連しており、これらのマーカーはCHF患者の診断とモニタリングの両方に用いられています。心筋梗塞（MI）では、トロポニンI、トロポニンT、クレアチンキナーゼ-MB（CK-MB）が心筋梗塞の心臓マーカーとしてよく用いられます。トロポニンは心筋障害を検出するための高感度で特異的なマーカーです。トロポニンの上昇は心筋梗塞を示し、急性冠症候群の診断に役立ちます。

地域別洞察

南北アメリカは、心血管疾患の有病率が高く、医療施設が整備され、主要な市場参入企業が存在するため、市場情勢は重要です。心臓発作の発生率の増加、早期診断と早期治療への強い関心が、この地域における心臓マーカー試験の需要を促進しています。さらに、バイオテクノロジーセグメントの進歩や新規診断手法の採用率の高さも、アメリカの心臓マーカー市場成長に寄与しています。欧州の心臓マーカー市場成長は、冠動脈性心疾患などの慢性疾患に罹患しやすい高齢化人口の増加が後押ししています。最先端の医療施設の利用可能性、医療費の増加、有利な規制政策も欧州の心臓マーカー市場の成長を支えています。さらに、心臓バイオマーカーセグメントでは、複数の主要市場参入企業と継続的な研究活動が市場成長をさらに刺激しています。アジア太平洋は、予測期間中に心臓マーカー市場の著しい成長率を示すと予測されています。これは、大規模な人口基盤、生活習慣病の罹患率の上昇、新興経済諸国における医療インフラの緩やかな改善によるものです。

FPNVポジショニングマトリックス

FPNVポジショニングマトリックスは心臓マーカー市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を記載しています。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます。フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、心臓マーカー市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、このセグメントの競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています。

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を記載しています。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発とイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を記載しています。

本レポートは、以下のような主要な質問に対応しています。

1.心臓マーカー市場の市場規模と予測は？

2.心臓マーカー市場の予測期間中に投資を検討すべき製品、用途は何か？

3.心臓マーカー市場の技術動向と規制枠組みは？

4.心臓マーカー市場における主要ベンダーの市場シェアは？

5.心臓マーカー市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 心血管疾患の発生増加
    • 心臓バイオマーカー用の多種多様な試薬やキットへのアクセス
    • 各国の医療インフラと支出の改善
  • 抑制要因
    • 心臓血管の処置と治療に関連する高価格
  • 機会
    • 心臓マーカーの継続的な進歩
    • ポイントオブケア診断ソリューションの本質を継続的に改善
  • 課題
    • 心臓マーカーに対する厳格な規制と承認
• 市場セグメンテーション分析
  • 製品：心臓特異的タンパク質の定性的と定量的評価を提供する試薬とキット
  • バイオマーカータイプ：心不全の診断と管理におけるBNPとNT-proBNPバイオマーカーの採用率が高い
  • エンドユーザー：実験室試験施設における心臓マーカーの重要な利用
  • 適応症：うっ血性心不全の状況における心臓マーカーの潜在的な採用
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 心臓マーカー市場：製品別

• イントロダクション
• 機器
• 試薬とキット

第7章 心臓マーカー市場：バイオマーカータイプ別

• イントロダクション
• BNPまたはNT-ProBNP
• CK-MB
• Hs-CRP
• ミオグロビン
• トロポニンIとT

第8章 心臓マーカー市場：エンドユーザー別

• イントロダクション
• 実験室試験施設
• ポイントオブケア試験施設

第9章 心臓マーカー市場：適応症別

• イントロダクション
• うっ血性心不全
• 心筋梗塞

第10章 南北アメリカの心臓マーカー市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の心臓マーカー市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの心臓マーカー市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

第14章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. CARDIAC MARKER MARKET RESEARCH PROCESS
• FIGURE 2. CARDIAC MARKER MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CARDIAC MARKER MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CARDIAC MARKER MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL CARDIAC MARKER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. CARDIAC MARKER MARKET DYNAMICS
• FIGURE 7. GLOBAL CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL CARDIAC MARKER MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL CARDIAC MARKER MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL CARDIAC MARKER MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL CARDIAC MARKER MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES CARDIAC MARKER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES CARDIAC MARKER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. CARDIAC MARKER MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. CARDIAC MARKER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CARDIAC MARKER MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CARDIAC MARKER MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL CARDIAC MARKER MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL CARDIAC MARKER MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL CARDIAC MARKER MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL CARDIAC MARKER MARKET SIZE, BY CHEMILUMINESCENCE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL CARDIAC MARKER MARKET SIZE, BY CHEMILUMINESCENCE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL CARDIAC MARKER MARKET SIZE, BY ELISA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL CARDIAC MARKER MARKET SIZE, BY ELISA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL CARDIAC MARKER MARKET SIZE, BY IMMUNOCHROMATOGRAPHY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL CARDIAC MARKER MARKET SIZE, BY IMMUNOCHROMATOGRAPHY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL CARDIAC MARKER MARKET SIZE, BY IMMUNOFLUORESCENCE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL CARDIAC MARKER MARKET SIZE, BY IMMUNOFLUORESCENCE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL CARDIAC MARKER MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL CARDIAC MARKER MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL CARDIAC MARKER MARKET SIZE, BY BNP OR NT-PROBNP, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL CARDIAC MARKER MARKET SIZE, BY BNP OR NT-PROBNP, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL CARDIAC MARKER MARKET SIZE, BY CK-MB, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL CARDIAC MARKER MARKET SIZE, BY CK-MB, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL CARDIAC MARKER MARKET SIZE, BY HS-CRP, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL CARDIAC MARKER MARKET SIZE, BY HS-CRP, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL CARDIAC MARKER MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL CARDIAC MARKER MARKET SIZE, BY MYOGLOBIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL CARDIAC MARKER MARKET SIZE, BY TROPONIN I & T, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL CARDIAC MARKER MARKET SIZE, BY TROPONIN I & T, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL CARDIAC MARKER MARKET SIZE, BY LABORATORY TESTING FACILITIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL CARDIAC MARKER MARKET SIZE, BY LABORATORY TESTING FACILITIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL CARDIAC MARKER MARKET SIZE, BY POINT OF CARE TESTING FACILITIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL CARDIAC MARKER MARKET SIZE, BY POINT OF CARE TESTING FACILITIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL CARDIAC MARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL CARDIAC MARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL CARDIAC MARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL CARDIAC MARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. AMERICAS CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 48. AMERICAS CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 49. AMERICAS CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 50. AMERICAS CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 51. AMERICAS CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 52. AMERICAS CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 53. AMERICAS CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 54. AMERICAS CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 55. AMERICAS CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 56. AMERICAS CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 57. AMERICAS CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 58. AMERICAS CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 59. ARGENTINA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 60. ARGENTINA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 61. ARGENTINA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 62. ARGENTINA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 63. ARGENTINA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 64. ARGENTINA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 65. ARGENTINA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 66. ARGENTINA CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 67. ARGENTINA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 68. ARGENTINA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 69. BRAZIL CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 70. BRAZIL CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 71. BRAZIL CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 72. BRAZIL CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 73. BRAZIL CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 74. BRAZIL CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 75. BRAZIL CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 76. BRAZIL CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 77. BRAZIL CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 78. BRAZIL CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 79. CANADA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 80. CANADA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 81. CANADA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 82. CANADA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 83. CANADA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 84. CANADA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 85. CANADA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 86. CANADA CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 87. CANADA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 88. CANADA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 89. MEXICO CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 90. MEXICO CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 91. MEXICO CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 92. MEXICO CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 93. MEXICO CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 94. MEXICO CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 95. MEXICO CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 96. MEXICO CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 97. MEXICO CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 98. MEXICO CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 99. UNITED STATES CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 100. UNITED STATES CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 101. UNITED STATES CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 102. UNITED STATES CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 103. UNITED STATES CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 104. UNITED STATES CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 105. UNITED STATES CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 106. UNITED STATES CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 107. UNITED STATES CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 108. UNITED STATES CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 109. UNITED STATES CARDIAC MARKER MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 110. UNITED STATES CARDIAC MARKER MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 112. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 114. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 116. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 118. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 119. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 120. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 121. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 122. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 123. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 124. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 125. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 126. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 127. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 128. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 129. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 130. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 131. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 132. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 133. CHINA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 134. CHINA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 135. CHINA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 136. CHINA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 137. CHINA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 138. CHINA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 139. CHINA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 140. CHINA CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 141. CHINA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 142. CHINA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 143. INDIA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 144. INDIA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 145. INDIA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 146. INDIA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 147. INDIA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 148. INDIA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 149. INDIA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 150. INDIA CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 151. INDIA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 152. INDIA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 153. INDONESIA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 154. INDONESIA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 155. INDONESIA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 156. INDONESIA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 157. INDONESIA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 158. INDONESIA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 159. INDONESIA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 160. INDONESIA CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 161. INDONESIA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 162. INDONESIA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 163. JAPAN CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 164. JAPAN CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 165. JAPAN CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 166. JAPAN CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 167. JAPAN CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 168. JAPAN CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 169. JAPAN CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 170. JAPAN CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 171. JAPAN CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 172. JAPAN CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 173. MALAYSIA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 174. MALAYSIA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 175. MALAYSIA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 176. MALAYSIA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 177. MALAYSIA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 178. MALAYSIA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 179. MALAYSIA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 180. MALAYSIA CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 181. MALAYSIA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 182. MALAYSIA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 183. PHILIPPINES CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 184. PHILIPPINES CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 185. PHILIPPINES CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 186. PHILIPPINES CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 187. PHILIPPINES CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 188. PHILIPPINES CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 189. PHILIPPINES CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 190. PHILIPPINES CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 191. PHILIPPINES CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 192. PHILIPPINES CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 193. SINGAPORE CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 194. SINGAPORE CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 195. SINGAPORE CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 196. SINGAPORE CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 197. SINGAPORE CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 198. SINGAPORE CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 199. SINGAPORE CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 200. SINGAPORE CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 201. SINGAPORE CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 202. SINGAPORE CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 203. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 204. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 205. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 206. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 207. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 208. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 209. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 210. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 211. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 212. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 213. TAIWAN CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 214. TAIWAN CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 215. TAIWAN CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 216. TAIWAN CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 217. TAIWAN CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 218. TAIWAN CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 219. TAIWAN CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 220. TAIWAN CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 221. TAIWAN CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 222. TAIWAN CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 223. THAILAND CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 224. THAILAND CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 225. THAILAND CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 226. THAILAND CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 227. THAILAND CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 228. THAILAND CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 229. THAILAND CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 230. THAILAND CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 231. THAILAND CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 232. THAILAND CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 233. VIETNAM CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 234. VIETNAM CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 235. VIETNAM CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 236. VIETNAM CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 237. VIETNAM CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 238. VIETNAM CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 239. VIETNAM CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 240. VIETNAM CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 241. VIETNAM CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 242. VIETNAM CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 251. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 252. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 253. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 254. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 255. DENMARK CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 256. DENMARK CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 257. DENMARK CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 258. DENMARK CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 259. DENMARK CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 260. DENMARK CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 261. DENMARK CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 262. DENMARK CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 263. DENMARK CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 264. DENMARK CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 265. EGYPT CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 266. EGYPT CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 267. EGYPT CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 268. EGYPT CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 269. EGYPT CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 270. EGYPT CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 271. EGYPT CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 272. EGYPT CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 273. EGYPT CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 274. EGYPT CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 275. FINLAND CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 276. FINLAND CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 277. FINLAND CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 278. FINLAND CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 279. FINLAND CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 280. FINLAND CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 281. FINLAND CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 282. FINLAND CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 283. FINLAND CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 284. FINLAND CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 285. FRANCE CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 286. FRANCE CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 287. FRANCE CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 288. FRANCE CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 289. FRANCE CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 290. FRANCE CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 291. FRANCE CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 292. FRANCE CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 293. FRANCE CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 294. FRANCE CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 295. GERMANY CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 296. GERMANY CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 297. GERMANY CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 298. GERMANY CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 299. GERMANY CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 300. GERMANY CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 301. GERMANY CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 302. GERMANY CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 303. GERMANY CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 304. GERMANY CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 305. ISRAEL CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 306. ISRAEL CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 307. ISRAEL CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 308. ISRAEL CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 309. ISRAEL CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 310. ISRAEL CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 311. ISRAEL CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 312. ISRAEL CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 313. ISRAEL CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 314. ISRAEL CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 315. ITALY CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 316. ITALY CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 317. ITALY CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 318. ITALY CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 319. ITALY CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 320. ITALY CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 321. ITALY CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 322. ITALY CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 323. ITALY CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 324. ITALY CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 325. NETHERLANDS CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 326. NETHERLANDS CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 327. NETHERLANDS CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 328. NETHERLANDS CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 329. NETHERLANDS CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 330. NETHERLANDS CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 331. NETHERLANDS CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 332. NETHERLANDS CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 333. NETHERLANDS CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 334. NETHERLANDS CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 335. NIGERIA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 336. NIGERIA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 337. NIGERIA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 338. NIGERIA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 339. NIGERIA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 340. NIGERIA CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 341. NIGERIA CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 342. NIGERIA CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 343. NIGERIA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 344. NIGERIA CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 345. NORWAY CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 346. NORWAY CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 347. NORWAY CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 348. NORWAY CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 349. NORWAY CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 350. NORWAY CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 351. NORWAY CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 352. NORWAY CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 353. NORWAY CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 354. NORWAY CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 355. POLAND CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 356. POLAND CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 357. POLAND CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 358. POLAND CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 359. POLAND CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 360. POLAND CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 361. POLAND CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 362. POLAND CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 363. POLAND CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 364. POLAND CARDIAC MARKER MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 365. QATAR CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 366. QATAR CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 367. QATAR CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 368. QATAR CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 369. QATAR CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
• TABLE 370. QATAR CARDIAC MARKER MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
• TABLE 371. QATAR CARDIAC MARKER MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 372. QATAR CARDIAC MARKER MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 373. QATAR CARDIAC MARKER MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 374. QATAR CARDIAC MARKER

[189 Pages Report] The Cardiac Marker Market size was estimated at USD 3.81 billion in 2023 and expected to reach USD 4.16 billion in 2024, at a CAGR 9.71% to reach USD 7.29 billion by 2030.

Cardiac markers are substances or molecules measured in the blood to diagnose and monitor various cardiac conditions, particularly those related to heart muscle damage or stress. These markers are often used in clinical settings, such as hospitals and laboratories, to assist in diagnosing, prognosis, and monitoring cardiovascular diseases. They are particularly widely used in the diagnosis of conditions such as myocardial infarction and other forms of acute coronary syndrome. With an increased emphasis on accurate and early diagnosis in cases of cardiovascular diseases (CVD), the cardiac markers market's valuation has been progressively escalating. The rising incidence of cardiovascular conditions and the growing global geriatric population fuel the market demand for cardiac markers. Rising demand for point-of-care testing and the steady development in healthcare infrastructure, including well-equipped labs and trained personnel, globally aids the industry's growth. However, High prices associated with cardiovascular procedures and solutions affect market adoption. The evolution of the biomedical industry, particularly diagnostic technologies, and government healthcare initiatives and programs aiming to foster preventative care are instrumental in escalating the demand for cardiac markers and creating a significant growth opportunity for the market.

Product: Reagents and kits provide qualitative and quantitative assessment of cardiac-specific proteins

Chemiluminescence immunoassay (CLIA) systems are sophisticated diagnostic instruments that detect high-sensitivity cardiac markers such as troponin, CK-MB, and myoglobin. These instruments utilize luminogenic substrates that emit light upon reaction with specific enzymes in the presence of the targeted antigen. Enzyme-linked immunosorbent assay (ELISA) kits and instruments are vital in detecting and quantifying cardiac markers. These assays rely on an enzyme-conjugate reaction that produces a measurable colorimetric change. ELISA systems offer flexibility in terms of scalability and are known for their specificity and high sensitivity. Immunochromatography is a rapid and simple diagnostic technique that utilizes the movement of particles along a membrane via capillary action. It involves using antibodies and antigens to detect specific biomarkers, such as cardiac markers. Immunofluorescence is a technique that uses fluorescent dyes or markers to detect the presence of specific antibodies or antigens, and it is employed for more detailed and specific analysis in the context of cardiac markers. Reagents and kits for cardiac marker detection comprise a wide range of immunoassays optimized for various analytical platforms. These consumables often include antibodies, antigens, buffers, and substrates specifically engineered for the qualitative and quantitative assessment of cardiac-specific proteins.

Biomarker Type: High adoption of BNP and NT-proBNP biomarkers for diagnosing and managing heart failure

BNP and NT-proBNP are biomarkers for diagnosing and managing heart failure. BNP is discharged by ventricular myocytes in reaction to increased wall tension, typically due to fluid overload in heart failure. When found at low levels, these peptides have a strong negative predictive value for cardiac risk and heart failure. In contrast, elevated levels are indicative of an increased risk of adverse cardiovascular events. Creatine Kinase-MB (CK-MB) is an isoenzyme of creatine kinase (CK) and is one of the traditional biomarkers for diagnosing myocardial infarction (MI). It is found mainly in cardiac cells and increases in the blood following the death of heart muscle cells. High-sensitivity C-Reactive Protein (Hs-CRP) is an acute-phase protein and a non-specific inflammatory biomarker that can indicate systemic inflammation. It is often used to assess the risk of cardiac disease and other cardiac risk factors. Myoglobin is an early but non-specific marker of myocardial injury. It is most valuable when used alongside more specific cardiac markers, such as troponins, for the early assessment of myocardial infarction. Troponin I and T are regulatory proteins that are part of the cardiac muscle contractile apparatus and are highly specific and sensitive biomarkers for myocardial injury.

End-User: Significant utilization of cardiac marker in laboratory testing facilities

Laboratory testing facilities are typically equipped with sophisticated equipment and skilled personnel capable of performing a comprehensive range of tests. Hospitals and independent diagnostic labs are the primary constituents of this sector. They offer accurate and high-volume cardiac marker testing services, integral for diagnosing various cardiovascular conditions, including myocardial infarctions (heart attacks) and acute coronary syndromes. Point of Care (POC) testing facilities include emergency departments, ambulances, clinics, and physician offices. The immediacy of results allows for swift clinical decision-making, critical in managing cardiac emergencies. POC testing for cardiac markers, such as troponin, BNP (B-type natriuretic peptide), and D-dimer, has revolutionized diagnosing and managing cardiovascular diseases. POCT systems for cardiac markers are designed for simplicity and speed, reducing the turnaround time for decision-making in acute care settings.

Indication: Potential adoption of cardiac markers in congestive heart failure situations

In congestive heart failure (CHF) situations, cardiac markers are crucial in diagnosis, prognosis, and management. B-type natriuretic peptide (BNP) and N-terminal-pro BNP (NT-proBNP) are the primary biomarkers used to confirm suspected CHF, differentiate it from other causes of dyspnea, and assess the severity of the condition. Elevated levels of BNP or NT-proBNP are associated with heart failure, and these markers are used for both diagnosis and monitoring of CHF patients. In myocardial infarction (MI), Troponin I, Troponin T, and creatine kinase-MB (CK-MB) are commonly used cardiac markers for myocardial infarction. Troponins are sensitive and specific markers for detecting myocardial injury. Elevated levels of troponins indicate myocardial infarction and help in diagnosing acute coronary syndrome.

Regional Insights

The Americas has a significant market landscape in the cardiac marker market due to a high prevalence of cardiovascular diseases, well-established healthcare facilities, and major market players. The increasing incidence of heart attacks and the strong focus on early diagnosis and treatment are driving the demand for cardiac marker tests in this region. Moreover, advancements in the biotechnology sector and higher adoption rates for novel diagnostics methodologies contribute to America's cardiac marker market growth. Europe's market growth in the cardiac marker is propelled by the rising aging population, which is more prone to chronic diseases, including coronary heart disease. The availability of cutting-edge healthcare facilities, rising healthcare expenditures, and favorable regulatory policies also support the growth of the European cardiac marker market. Moreover, several key market players and ongoing research activities in the cardiac biomarkers space further stimulate market growth. The Asia-Pacific region is projected to show a significant cardiac marker market growth rate during the forecast period attributed to the large population base, the rising incidences of lifestyle diseases, and the gradual improvement in healthcare infrastructure across emerging economies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cardiac Marker Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cardiac Marker Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cardiac Marker Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aehealth Limited, Becton, Dickinson and Company, BG Medicine Inc., Bio-Rad Laboratories, Inc., Biomerieux SA, Danaher Corporation, DiaSorin S.P.A., HyTest Ltd., LSI Medience Corporation, PerkinElmer Inc., QuidelOrtho Corporation, Randox Laboratories Ltd., Roche Diagnostics Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Trinity Biotech PLC.

Market Segmentation & Coverage

This research report categorizes the Cardiac Marker Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Instruments
    • Chemiluminescence
    • ELISA
    • Immunochromatography
    • Immunofluorescence

• Reagents & Kits

• Biomarker Type
  • BNP Or NT-ProBNP
  • CK-MB
  • Hs-CRP
  • Myoglobin
  • Troponin I & T

• End-User
  • Laboratory Testing Facilities
  • Point of Care Testing Facilities

• Indication
  • Congestive Heart Failure
  • Myocardial Infarction

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cardiac Marker Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cardiac Marker Market?

3. What are the technology trends and regulatory frameworks in the Cardiac Marker Market?

4. What is the market share of the leading vendors in the Cardiac Marker Market?

5. Which modes and strategic moves are suitable for entering the Cardiac Marker Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing occurrence of cardiovascular diseases
    • 5.1.1.2. Accessibility to a large variety of reagents and kits for cardiac biomarkers
    • 5.1.1.3. Improved healthcare infrastructure and spending across economies
  • 5.1.2. Restraints
    • 5.1.2.1. High prices associated with cardiovascular procedures and solutions
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing advancements in cardiac markers
    • 5.1.3.2. Persistent improvement in the essence of point-of-care diagnostic solution
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations and approvals for cardiac markers
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Reagents and kits provide qualitative and quantitative assessment of cardiac-specific proteins
  • 5.2.2. Biomarker Type: High adoption of BNP and NT-proBNP biomarkers for diagnosing and managing heart failure
  • 5.2.3. End-User: Significant utilization of cardiac marker in laboratory testing facilities
  • 5.2.4. Indication: Potential adoption of cardiac markers in congestive heart failure situations
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Cardiac Marker Market, by Product

• 6.1. Introduction
• 6.2. Instruments
• 6.3. Reagents & Kits

7. Cardiac Marker Market, by Biomarker Type

• 7.1. Introduction
• 7.2. BNP Or NT-ProBNP
• 7.3. CK-MB
• 7.4. Hs-CRP
• 7.5. Myoglobin
• 7.6. Troponin I & T

8. Cardiac Marker Market, by End-User

• 8.1. Introduction
• 8.2. Laboratory Testing Facilities
• 8.3. Point of Care Testing Facilities

9. Cardiac Marker Market, by Indication

• 9.1. Introduction
• 9.2. Congestive Heart Failure
• 9.3. Myocardial Infarction

10. Americas Cardiac Marker Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Cardiac Marker Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Cardiac Marker Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Mindray Expands Cardiac Biomarker Portfolio with Launch of New Assays
  • 13.3.2. AUDIT MicroControls, Inc. Announces Linearity FLQ Cardiac Markers for Roche Systems
  • 13.3.3. Cipla Launches Diagnostic Device For Multiple Health Conditions
• 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio